Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design

Journal of Medicinal Chemistry

Volumn 50, Issue 10, 2007, Pages 2289-2292

  Donald, Alastair ^a   McHardy, Tatiana ^a   Rowlands, Martin G ^a   Hunter, Lisa Jane K ^a   Davies, Thomas G ^b   Berdini, Valerio ^b   Boyle, Robert G ^b   Aherne, G Wynne ^a   Garrett, Michelle D ^a   Collins, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHENYLPURINE; CHIMERIC PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; MITOSIS INHIBITION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34249069460     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0700924     Document Type: Article

References (28)

1. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discovery 2005, 4, 988-1004.
2. Georgiakis, G. V.; Younes, A. From Rapa Nui to rapamycin: Targeting PI3K/Akt/mT0R for cancer therapy. Expert Rev. Anti-cancer Ther. 2006, 6, 131-140.
3. Cheng, J. Q.; Lindsley, C. W.; Cheng, G. Z.; Yang, H.; Nicosia, S. V. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 2005, 24, 7482-7492.
4. Cully, M.; You, H.; Levine, A. J.; Mak, T. W. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6, 184-192.
5. Fan, Q. W.; Knight, Z. A.; Goldenberg, D. D.; Yu, W.; Mostov, K. E.; Stokoe, D.; Shokat, K. M.; Weiss, W. A. A dual PI3 kinase/ mTOR inihibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9, 341-349.
6. Luo, Y.; Shoemaker, A. R.; Liu, X.; Woods, K. W.; Thomas, S. A.; de Jong, R.; Han, E. K; Li, T.; Stoll, V. S.; Powlas, J. A.; Oleksijew, A.; Mitten, M. J.; Shi, Y.; Guan, R.; McGonigal, T. P.; Klinghofer, V.; Johnson, E. F.; Leverson, J. D.; Bouska, J. J.; Mamo, M.; Smith, R. A.; Gramling-Evans, E. E.; Zinker, B. A.; Mika, A. K.; Nguyen, P. T.; Oltersdorf, T.; Rosenberg, S. H.; Li, Q.; Giranda, V. L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 2005, 4, 977-986.
7. Barnett, S. F.; Bilodeau, M. T.; Lindsley, C. W. The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progression towards target validation. Curr. Top. Med. Chem. 2005, 5, 109-125.
8. Woods, K. W.; Fischer, J. P.; Claiborne, A.; Li, T.; Thomas, S. A,; Zhu, G.; Diebold, R. B.; Liu, X.; Shi, Y.; Klinghofer, V.; Han, E. K.; Guan, R.; Magnone, S. R.; Johnson, E. F.; Bouska, J. J.; Olson, A. M.; de Jong, R.; Oltersdorf, T.; Luo, Y.; Rosenberg, S. H,; Giranda, V. L.; Li, Q. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg. Med. Chem. 2006, 14, 6832-6846.
9. (a) Breitenlechner, C. B.; Wegge, T.; Berillon, L.; Graul, K; Marzenell, K.; Friebe, W. G.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R. A,; Masjost, B. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem. 2004, 47, 1375-1390.
10. (b) Breitenlechner. C. B.; Friebe, W. G.; Brunet, E. Werner, G.; Graul, K.; Thomas, U.; Kunkele, K. P.; Schafer, W. Gassel, M.; Bossemeyer, D.; Huber, R.; Engh, R. A,; Masjost, B. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem. 2005, 48, 163-170.
11. Burns, S.; Travers, J.; Collins, I.; Rowlands, M. G.; Newbatt, Y.; Thompson, N.; Garrett, M. D.; Workman, P.; Aherne, G. W. Identification of small molecule inhibitors of protein kinase B (PKB) in an AlphaScreen high-throughput screen. J. Biomol. Screening 2006, 11, 822-827.
12. Collins, I.; Caldwell, J.; Fonseca, T.; Donald, A.; Bavetsias, V.; Rowlands, M. G.; Hunter, L-J. K.; Garrett, M. D.; Davies, T. G.; Berdini, V.; Woodhead, S.; Davis, D.; Seavers. L. C. A.; Wyatt, P. G.; McDonald, E. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg. Med. Chem. 2006, 14, 1255-1273.
13. Reuveni, H.; Livnah, N.; Geiger, T.; Klein, S.; Ohne, O.; Cohen, L; Benhar, M.; Gellerman, G.; Levitski, A. Toward a PKB inhibitor: Modification of a selective PKA inhibitor by rational design. Biochemistry 2002, 41, 10304-10314.
14. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discovery 2004, 8, 660-672.
15. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 2002, 9, 940-944.
16. Gassell, M.; Breitenlechner, C. B.; Ruger, P.; Jucknischke, U.; Schneider, T.; Huber, R.; Bossemeyer, D.; Engh, R. A. Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). J. Mol. Biol. 2003, 329, 1021-1034.
17. Davies, T. G.; Verdonk, M. L.; Graham, B.; Saalau-Bethell, S.; Hamlett, C. C.; McHardy, T.; Collins, I.; Garrett, M. D.; Workman, P.; Woodhead, S. J.; Jhoti, H.;. Barford, D. A structural comparison of inhibitor binding to PKB, PKA. and PKA-PKB chimera. J. Mol. Biol. 2007, 367, 882-894.
18. Havelkova, M.; Hocek, M.; Cesnek, M.; Dvorak, D. The Suzuki-Miyaura cross-coupling reactions of 6-halopurines with boronic acids leading to 6-aryl- and 6-phenylpurines. Synlett 1999, 1145-1147.
19. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
20. Liu, G.; Cogan, D. A.; Ellman, J. A. Catalytic asymmetric synthesis of tert-butanesulfinamide. Application to the asymmetric synthesis of amines. J. Am. Chem. Soc. 1997, 119, 9913-9914.
21. ClogP and TPSA calculated using ChemDraw Ultra 10.0; CambridgeSoft: Cambridge, MA, 2007.
22. Amschler, U.; Schultz, O. E. Halogen derivatives of epinephrine and isoproterenol. Arzneim.-Forsch. 1972, 22, 2095-2096.
23. Berdini, V.; Boyle, R. G.; Saxty, G.; Verdonk, M. L.; Woodhead, S. J.; Wyatt, P. G.; Sore, H. F.; Caldwell. J.; Collins. I.; Da Fonseca, T. F.; Donald, A. PCT Intl. Pat. Appl. 046023: Chem. Abstr. 2006, 144, 450718.
24. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of novel inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem. 2007, 50, 2293-2296.
25. Garrett, M. D.; Hunter, L. J.; Faria Da Fonseca, T.; Caldwell, J.; Rowlands, M. G.; Hardcastle, A.; Collins, I.; McDonald, E.; Thompson, N.; Workman, P. 322. Novel isoquinoline-5-sulfonamides as biochemical and cellular inhibitors of PKB/Akt. Eur. J. Cancer Suppl. 2004, 2 (8), 98.
26. Harrington, L. S.; Findlay, G. M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, J.; Leslie, N. R.; Cheng, S.; Shepherd, P. R.; Gout, I.; Downes, C. P.; Lamb. R. F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166, 213-223.
27. Bossis, I.; Stratakis, C. A. Minireview: PRKAR1A: Normal and abnormal functions. Endocrinology 2004, 145, 5452-5458.
28. Bossis, I.; Voutetakis, A.; Bei, T.; Sandrini, F.; Griffin, K. J.; Stratakis, C. A. Protein kinase A and its role in human neoplasia: The Carney complex paradigm. Endocr.-Relat. Cancer 2004, 11, 265-280.